adx her2 mutation detection kit (amoy diagnostics, xiamen, china) (Amoy Diagnostics)
90
Structured Review
Amoy Diagnostics
adx her2 mutation detection kit (amoy diagnostics, xiamen, china)
Adx Her2 Mutation Detection Kit (Amoy Diagnostics, Xiamen, China), supplied by Amoy Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/adx+her2+mutation+detection+kit/human+egfr+gene+mutation+detection+kit/pmc11194746-118-1-6
Average 90 stars, based on 1 article reviews
Adx Her2 Mutation Detection Kit (Amoy Diagnostics, Xiamen, China), supplied by Amoy Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/adx+her2+mutation+detection+kit/human+egfr+gene+mutation+detection+kit/pmc11194746-118-1-6
Average 90 stars, based on 1 article reviews
adx her2 mutation detection kit (amoy diagnostics, xiamen, china) - by Bioz Stars,
2026-09
90/100 stars
Images
1) Product Images from "A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations"
Article Title: A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations
Journal: Cancer Medicine
doi: 10.1002/cam4.7335
Figure Legend Snippet: Baseline Characteristics of HER2‐Mutant patients in first‐line treatment.
Techniques Used:
Figure Legend Snippet: Kaplan–Meier survival curves of PFS in HER2 mutation. (A) Chemotherapy + ICIs versus chemotherapy; (B) PD‐L1 Negative versus PD‐L1 Positive; (C) chemotherapy + bevacizumab versus chemotherapy; (D) chemotherapy + bevacizumab versus chemotherapy + ICIs; (E) pyrotinib versus chemotherapy; (F) pyrotinib versus chemotherapy + ICIs.
Techniques Used: Mutagenesis
Figure Legend Snippet: Clinical and pathological characteristics of HER2‐mutant patients treated with pyrotinib after first‐line treatment progression in this study.
Techniques Used:
Figure Legend Snippet: HER2‐mutant patients treated with pyrotinib after first‐line treatment progression. (A) Survival benefits of Pyrotinib based on treatment data and line of treatment. (B) Kaplan–Meier survival curves of PFS based on first‐line treatment PFS; (C) univariate analysis; (D) multivariate analysis.
Techniques Used: Mutagenesis
Figure Legend Snippet: Summary of genomic landscape and clinical features in HER2‐Mutant NSCLC with immunotherapy. (A) Mutation frequency; (B) Kaplan–Meier survival curves of OS; (C) OncoPrint that top 20 gene alterations.
Techniques Used: Mutagenesis
Figure Legend Snippet: Reported retrospective studies on the efficacy of first‐line treatment for advanced NSCLC with HER2‐Mutant.
Techniques Used: Control
Related Articles
Mutagenesis:Article Title: Outcomes of Pemetrexed-based chemotherapies in HER2 -mutant lung cancers Article Snippet: .. Article Title: A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations Article Snippet: .. In the first‐line treatment cohort, the inclusion criteria were as follows: (1) age ≥ 18 years, (2) HER2 mutations detected at the time of initial diagnosis through next‐generation sequencing (NGS) or Article Title: Pyrotinib in <i>HER2</i>-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study Article Snippet: Eligible patients were 18-75 years old and had histologically or cytologically confirmed HER2-mutant NSCLC (adenocarcinoma) with unresectable stage IIIB or IV disease according to the seventh edition of the International Association for the Study of Lung Cancer staging system.28 HER2 mutation was tested using an ADx HER2 Mutation Detection Kit (Amoy Diagnostics, Xiamen, China) at a central laboratory (WuXi NextCODE, Shanghai, China). Article Title: HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib Article Snippet: .. Article Title: Pyrotinib in <i>HER2</i>-Mutant Advanced Lung Adenocarcinoma After Platinum-Based Chemotherapy: A Multicenter, Open-Label, Single-Arm, Phase II Study Article Snippet: RESULTS Between October 20, 2016, and December 10, 2018, 60 patients received pyrotinib monotherapy.. At baseline, 58 (96.7%) were stage IV, and 25 (41.7%) received at least 2 lines of prior chemotherapy.. As of data cutoff on June 20, 2019, IRC-assessed objective response rate was 30.0% (95% CI, 18.8% to 43.2%). Amplification:Article Title: Outcomes of Pemetrexed-based chemotherapies in HER2 -mutant lung cancers Article Snippet: .. Biomarker Discovery:Article Title: A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations Article Snippet: .. In the first‐line treatment cohort, the inclusion criteria were as follows: (1) age ≥ 18 years, (2) HER2 mutations detected at the time of initial diagnosis through next‐generation sequencing (NGS) or Next-Generation Sequencing:Article Title: A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations Article Snippet: .. In the first‐line treatment cohort, the inclusion criteria were as follows: (1) age ≥ 18 years, (2) HER2 mutations detected at the time of initial diagnosis through next‐generation sequencing (NGS) or Article Title: HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib Article Snippet: .. Sequencing:Article Title: HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib Article Snippet: .. |